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Abstract 
Purpose: To investigate the toxicity of Labisia pumila standardized extract (LPE) and its liposomal 
extract (LLP). 
Methods: For acute toxicity study, LPE or LLP was orally administered (2000 mg/kg) in single doses to 
Sprague Dawley rats and the routine activity of the rats was continuously monitored for a total of 14 
days. After 14 days of treatment, all rats were sacrificed and their vital organs were excised, weighed 
and macroscopically examined, while for a repeated dose toxicity study, the rats were orally 
administered with LPE or LLP at the selected doses (250, 500 and 1000 mg/kg) for a period of 28 days. 
The animals were sacrificed (anaesthetized by sodium pentobarbitone and blood was collected by 
cardiac puncture), followed by examination of their body organs and blood serum. 
Results: LPE and LLP at 2000 mg/kg did not produce mortality or significant changes in the general 
behaviour, body weight and organ gross appearance of the rats. In repeated dose toxicity study no 
significant changes in, growth, organ weights, haematological parameters, biochemical values and 
histological features of vital organs of the treated groups, compared to the control group.  
Conclusion: The no-adverse-effect-level for LPE and LLP is (1000 mg/kg/day) when administered 
orally for 28 days. 
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Labisia pumila Blume, var. alata (Family: 
Myrsinaceae), known as Kacip Fatimah in 
Malaysia. Traditionally, L. pumila has been used 
due to its medicinal values in health products and 
female tonics. Furthermore, L. pumila is used in 
other ailments such as dysmenorrhoea, 
gonorrhoea, dysentery and flatulence [1]. Recent 
pharmacological studies have reported that L. 
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pumila has phytoestrogenic, anti-agiogenesis, 
anticancer, antioxidant, antibacterial, antifungal, 
anti-aging and anti-inflammatoryactivities. The 
benefits of the traditional use of L. pumila have 
also been supported by identification and 
isolation of many active compounds including 
phenolics, flavonoids and resorcinol compounds 
[2]. Gallic acid (as one of the isolated compounds 
from this plant) possessed many 
pharmacological activities such as antioxidant, 
antiangiogenesis, antiobesity, and anticancer 
effects. Rutin is also reported for different 
pharmacological effects, for example hepatic 
protective, antidiabetic, antihypertensive, anti-
inflammatory, anticancer and antioxidant 
activities. Gallic acid and rutin both found in L. 
pumila extract [3-8]. Sub-acute, teratogenic and 
reproductive toxicity studies of L. pumila water 
extract at (50, 1000 and 800 mg/kg), respectively 
without any side effects were reported [9-11]. 
The present study has been designed to perform 
the acute oral toxicity study at (2000 mg/kg) and 
repeated dose oral toxicity study of LPE and LLP 
at (250, 500 and 1000 mg/kg), respectively. 
Furthermore, the present study also describe 
authenticity of plant species, parts of plant, type 
of extract and method of extraction. So, this 
study was aimed to evaluate the acute and 
repeated dose oral toxicity studies on 
standardized L. pumila extract (LPE) and 




Chemical and reagents 
 
Soybean lecithin was procured from Hong Aun 
kimia Sdn Bhd., Malaysia. Acetone, chloroform 
and ethanol were obtained from Quality Reagent 
Chemical Malaysia. 
 
Preparation of LPE and LLP 
 
The whole plant of L. pumila var. alata was 
extracted with ethanol (50%) using soxhlet 
apparatus. The crude extract was filtered, 
concentrated under reduced pressure using a 
rotary evaporator, and further dried in oven. The 
dried extract was then kept in the fridge at -20oC 
prior to use. Liposome formulation of ethanol 
(50%) extract of L. pumila was prepared as 
described by [12]. 
 
Acute oral toxicity study 
 
Male and female Sprague Dawley rats at 8-10 
weeks of age were used. The animals were 
acclimatized to laboratory conditions for a week 
prior to the experiment. The rats were housed 
with free access to feed (normal laboratory chow, 
Gold Coin) and tap water ad libitum. The rats 
were maintained at 28±2°C under a light/dark 
cycle of 12 h. All the procedures were done 
according to the OECD guidelines (2008) [13 and 
15] and approved by the Animal Ethics 
Committee of Universiti Sains Malaysia 
(USM/Animal Ethics approval no. 2014/597). 
 
LPE and LLP were administered orally (2000 
mg/kg) in single doses to the rats (n=5). Another 
group of 5 rats without treatment was used as 
control group. The general behaviour of the rats 
were continuously monitored for 1 h after dosing, 
periodically during the first 24 h and daily 
thereafter for a total of 14 days. After 14 days of 
treatment, all animals were euthanized in CO2 
chamber, and selected vital organs were 
excised, weighed, and macroscopically 
examined [14]. 
 
Repeated dose toxicity study 
 
Animals (70 rats) were divided into 7 groups (5 
rats/sex/group) and received the test materials 
orally. Group 1 served as control receiving 
vehicle only. Animals in group 2 to group 7 
received 250, 500 and 1000 mg/kg of LPE or 
LLP, respectively. Animals were treated once 
daily consecutively for 28 days. The animals 
were observed daily for clinical signs and 
mortality. At the end of the experiment, animals 
were anaesthetized by sodium pentobarbitone 
and blood was collected by cardiac puncture 
from overnight fasted animals. Vital organs such 
as brain, heart, lungs, liver, spleen, kidneys, 
and testes/ovaries were removed and weighed. 
Haematological, biochemical and histological 
analysis were done [15]. Measurements were 




Data are expressed as mean ± standard error of 
mean (SEM) and were analysed using Statistical 
Package for the Social Sciences (SPSS 20.0, 





Toxicity of LPE and LLP 
 
For acute oral toxicity study, lethal effects were 
not observed after administration of LPE or LLP 
at dose (2000 mg/kg). No behavioural changes 
were observed during the observation period. 
There were no significant changes in the organ-
to-body weight ratios (Table 1) of the treated rats 
compared to normal control group. Therefore, the 
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LD50 value for oral administration of LPE and LLP 
was greater than 2000 mg/kg. 
 
In repeated dose oral toxicity study, there was no 
mortality of animals at any dose. Gross 
observations did not show any changes and all 
animals of both groups remain healthy. There 
were no abnormalities founded with respect to 
eye colour, touch response, salivation, grip 
strength and tail pinch. No locomotor 
dysfunction, convulsions or tremors were 
observed in all animals. 
 
There were no significant differences observed 
for the weekly body weight and organ-to-body 
weight ratios of rats treated with LPE or LLP for 
28 days (Table 2 and Table 3) except for LLP 
250 mg/kg, LPE 500 mg/kg, and LLP 500 mg/kg 
for female groups during 14 days as presented in 
Table 2. The haematology results (Table 4) 
showed no statistically significant differences in 
the values for treated groups compared to 
normal control group except for haemoglobin 
(Hb), packed cell volume (PCV), mean cell 
volume (MCV), and neutrophiles in female 
groups only but still within the normal range as 
previously reported [16]. A biochemical 
examination results are summarized in Table 5, 
the levels of biochemical parameters were not 
statistically significant compared to normal 
control groups except for urea and uric acid in 
female treated groups, and for total cholesterol 
(TC), triglycerides (TG), and high density 
lipoprotein (HDL) in female and male treated 
groups but remained within the normal range 
except for urea level in female treated groups 
(LPE 500 mg/kg and LLP at 250, 500, 1000 
mg/kg). Among the indicators of liver function, 
alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST) and alkaline 
phosphatase (ALP) were not affected by LPE or 
LLP in both male and female treated groups. 
 
The histological examination of liver and kidney 
tissues of normal control group and treated 
groups did not show any pathological 
abnormalities. Both control and treated groups 
showed normal hepatic architecture. Mild 
periportal inflammation was seen in female and 
male normal control groups (only 1 out of 5 rats), 
female LPE 500 mg/kg group (only 1 out of 5 
rats) and male LPE 250 and 1000 mg/kg groups 
(only 1 out of 5 rats), while it didn’t show any 
periportal chronic inflammation in liver of LLP 
treated groups in both male and female rats.  
 
 
Table 1: Organ-to-body weight ratios of rats treated with LPE and LLP for acute toxicity study 
 
Organ Normal control 
water (10 mL/kg) 
Treated group with LPE 
(2000 mg/kg) 
Treated group with LLP 
(2000 mg/kg) 
Heart 0.35±0.01 0.35±0.01 0.32±0.01 
Liver 3.12±0.09 2.85±0.08 3.11±0.09 
kidney (R) 0.32±0.01 0.33±0.01 0.31±0.01 
kidney (L) 0.32±0.01 0.32±0.01 0.32±0.01 
Lung 0.63±0.04 0.62±0.04 0.64±0.02 
adrenal (R) 0.02±0.00 0.02±0.00 0.02±0.00 
adrenal (L) 0.02±0.00 0.02±0.00 0.02±0.00 
Spleen 0.26±0.01 0.28±0.01 0.27±0.02 
Uterus 0.22±0.04 0.26±0.06 0.23±0.01 
Ovaries 0.18±0.03 0.19±0.02 0.19±0.01 
Thymus 0.19±0.01 0.21±0.02 0.18±0.01 
Brain 0.75±0.03 0.72±0.01 0.74±0.01 
Values are expressed as mean ± SEM. No significant difference between normal control group vs. treated 
groups, where R = right and L=left 
 
Table 2: Weekly body weight (g) of rats treated with LPE and LLP for 28 days 
 
Group  0 day 7 days 14 days 21 days 28 days 
Normal control  218.15±8.16 233.5±9.47 249.1±11.10 233.4±9.95 239.66±11.07 
LPE 250 mg/kg 217.96±7.38 226.77±6.73 233.9±8.85 224.5±9.57 235.74±9.27 
LPE 500 mg/kg 219.1±4.78 223.85±3.91 232.4±7.05 220.1±5.50 235.69±6.53 
LPE 1000 mg/kg 209.44±3.81 218.49±6.99 230.6±7.35 218±7.48 227.51±8.97 
LLP 250 mg/kg 217.49±7.63 226.84±5.82 226.53±6.16 235.94±7.02 228.24±6.82 
LLP 500 mg/kg 217.86±5.34 232.66±6.47 233.97±7.30 243.06±7.54 234.77±8.90 
LLP 1000 mg/kg 230.81±5.28 229.54±6.41 227.32±6.02 235.21±5.85 224.91±8.04 
Values are expressed as mean ±SEM. (n=10); * = p< 0.05, ** = p< 0.01, *** = p< 0.001 for treated groups vs. 
normal control 
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Table 3: Organ-to-body weight ratios of rats treated with LPE and LLP for 28 days 
 
% Organ weight/ 
Bodyweight 












Brain  0.74±0.025 0.75±0.025 0.75±0.16 0.75±0.035 0.74±0.02 0.73±0.025 0.72±0.05 
Heart  0.34±0.015 0.35±0.015 0.36±0.01 0.35±0.015 0.33±0.01 0.34±0.025 0.32±0.015 
Lung 0.60±0.025 0.61±0.04 0.63±0.03 0.62±0.065 0.57±0.025 0.57±0.025 0.58±0.045 
Liver 2.68±0.075 2.61±0.085 2.65±0.09 2.61±0.095 2.74±0.1 2.73±0.17 2.52±0.105 
Spleen 0.21±0.01 0.22±0.015 0.21±0.01 0.21±0.015 0.20±0.01 0.20±0.01 0.19±0.01 
Kidney (L) 0.32±0.015 0.32±0.01 0.30±0.02 0.32±0.015 0.30±0.015 0.30±0.015 0.29±0.01 
Kidney (R) 0.32±0.015 0.33±0.015 0.32±0.015 0.32±0.01 0.31±0.015 0.30±0.015 0.30±0.015 
Ovaries 0.34±0.025 0.34±0.025 0.32±0.02 0.32±0.02 0.35±0.025 0.33±0.02 0.32±0.02 
Uterus 0.42±0.04 0.41±0.035 0.40±0.03 0.39±0.035 0.40±0.03 0.42±0.025 0.40±0.03 
Thymus  0.20±0.02 0.17±0.025 0.19±0.025 0.21±0.035 0.19±0.025 0.19±0.025 0.19±0.03 
Values are expressed as mean ±SEM. (n=10). No statistical significant difference for treated groups vs. normal control. 
 
















Hb (g/dL) 169.3±2.58 167.20±2.49 162.60±13.91 170.10±4.23 154.60±2.36 160.30±3.40 154.90±1.19 
RBC (×1012/L) 9.23±0.18 9.18±0.14 8.17±0.93 9.04±0.20 8.25±0.16 8.71±0.14 8.46±0.13 
PCV (L/L) 0.52±0.01 0.53±0.01 0.49±0.06 0.53±0.02 0.48±0.02 0.49±0.01 0.46±0.01* 
MCV (gl) 56.90±0.97 58.20±0.91 59.80±1.52 58.50±1.38 58.30±1.31 55.50±1.03 54.30±0.44 
White cell count (x109/L) 5.32±0.96 4.44±0.40 4.69±0.96 6.32±1.06 4.08±0.68 3.70±0.63 3.50±0.84 
Neutrophil (×109/L) 1.73±0.38 1.63±0.17 1.89±0.59 1.83±0.38 1.19±0.19 0.83±0.07*** 0.76±0.17*** 
Lymphocytes (×109/L) 3.35±0.66 2.65±0.33 2.57±0.48 4.15±0.66 2.68±0.48 2.68±0.51 2.53±0.74 
Monocytes (×109/L) 0.16±0.05 0.11±0.03 0.14±0.07 0.17±0.05 0.13±0.03 0.17±0.04 0.14±0.27 
Eosinophils (×109/L) 0.10±0.02 0.12±0.02 0.16±0.07 0.115±0.03 0.13±0.03 0.13±0.02 0.12±0.01 
Platelets (×109/L) 1065.10±87.45 778±112.16 676.60±155.56 604±77.98 726.90±97.43 962.40±60.66 874.50±50.37 
Values are expressed as mean ±SEM. (n=10);* = p< 0.05, ** = p< 0.01, *** = p< 0.001 for treated groups vs. normal control. Hb = haemoglobin, RBC = red blood cells, PCV = 
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Urea (mmol/L) 8.00±0.27 8.00±0.37 8.69±0.34 8.06±0.36 6.96±0.31* 6.73±0.34** 6.06±0.34** 
Creatinine (umol/L) 49.20±2.14 54.20±2.19 54.10±2.47 47.90±3.51 45.20±2.14 43.00±1.95 41.10±3.48 
Uric acid (mmol/L) 0.13±0.01 0.14±0.01 0.13±0.01 0.12±0.01 0.15±0.03 0.13±0.02 0.13±0.02 
TP (g/L) 80.60±1.44 82.20±1.61 80.60±0.82 79.30±1.65 76.50±1.59 77.40±1.25 74.50±1.56 
ALP (U/L) 117.10±13.67 118.10±15.57 138.90±22.40 136.00±22.31 136.70±14.73 130.00±22.47 111.70±12.90 
AST (U/L) 274.20±12.59 299.20±17.50 272.90±16.60 310.80±20.74 233.60±20.84 244.90±24.20 227.90±24.87 
ALT (U/L) 50.80±3.17 56.00±3.08 54.40±4.55 50.50±3.14 59.20±9.17 53.80±10.52 43.80±4.74 
Glu. (mmol/L) 3.78±0.51 3.83±0.29 4.21±0.28 4.04±0.38 5.57±0.70 5.33±0.86 5.67±0.27 
TC (mmol/L) 3.02±0.18 3.30±0.27 3.13±0.16 3.02±0.23 1.68±0.10 1.80±0.16 1.68±0.13 
TG (mmol/L) 0.35±0.02 0.45±0.03* 0.43±0.02 0.42±0.03 0.71±0.06*** 0.73±0.12** 0.54±0.07** 
LDL (mmol/L) 1.09±0.21 1.41±0.25 1.15±0.19 1.13±0.43 0.95±0.07 1.02±0.13 0.98±0.12 
HDL (mmol/L) 1.77±0.17 1.69±0.17 1.82±0.12 1.70±0.22 0.41±0.03*** 0.45±0.04*** 0.46±0.05*** 
Values are expressed as mean ±SEM. (n= 10);* p< 0.05, ** p< 0.01, *** p< 0.001 for treated groups vs. normal control. TP = total protein, ALP = alkaline phosphate, AST = 
Aspartate aminotransferase, ALT = alanine aminotransferase, Glu = glucose, TC = cholesterol, TG = triglycerides, LDL = low density lipoprotein and HDL = high density 
lipoprotein.
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No ballooning degeneration, inflammation or 
other pathological abnormalities were observed 
in liver tissue samples of male and female rats 
(Plates 1 and 2). Kidney exhibited normal renal 
cortex containing normal glomeruli. Renal 
tubules were lined with typical cuboidal 
epithelium and had distinct lumen. Chronic 
pyelitis was observed in 1 female rat in normal 
control and LPE 1000 mg/kg groups (Plates 3 
and 4). Thus these changes were not considered 
to be treatment related in this study, because 
these microscopic changes were observed in 
normal control group. 
 
 
Plate 1: Effects of different doses of LPE on liver 
histology of female and male rats in repeated dose 
toxicity study for 28 days as assessed by H & E 
staining. (A): female normal control with arrow 
showing mild periportal chronic inflammation (1 out of 
5 rats) (B): male normal control with arrow showing 
mild periportal chronic inflammation (only 1 out of 5 
rats) (C) female treated group with 250 mg/kg of LPE 
(D) male treated group with 250 mg/kg of LPE with 
arrow showing mild periportal chronic inflammation 
(only 1 out of 5 rats) (E) female treated group with 500 
mg/kg of LPE with arrow showing mild periportal 
chronic inflammation (only 1 out of 5 rats) (F) male 
treated group with 500 mg/kg of LPE (G) female 
treated group with 1000 mg/kg of LPE (H) male 
treated group with 1000 mg/kg of LPE with arrow 
showing mild periportal chronic inflammation (only 1 
out of 5 rats)  (Magnification × 10). 
 
 
Plate 2: Effects of different doses of LLP on liver 
histology of female and male rats in repeated dose 
toxicity study for 28 days as assessed by H & E 
staining. (A) female treated group with 250 mg/kg of 
LLP (B) male treated group with 250 mg/kg of LLP (C) 
female treated group with 500 mg/kg of LLP (D) male 
treated group with 500 mg/kg of LLP (E) female 
treated group with 1000 mg/kg of LLP (F) male treated 
group with 1000 mg/kg of LLP (Magnification × 10) 
 
 
Plate 3: Effects of different doses of LPE on kidney 
histology of female and male rats in repeated dose 
toxicity study for 28 days as assessed by H & E 
staining (A): female normal control showing normal 
renal tubules with chronic pyelitis (only 1 out of 5 rats) 
(B): male normal control group (C): female treated 
group with 250 mg/kg of LPE (D): male treated group 
with 250 mg/kg of LPE (E): female treated group with 
500 mg/kg of LPE (F): male treated group with 500 
mg/kg of LPE (G): female treated group with 1000 
Saeed et al 
Trop J Pharm Res, August 2018; 17(8): 1563 
 
mg/kg of LPE showing normal tubules with chronic 
pyelitis (only 1 out of 5 rats) (H): male treated group 
with 1000 mg/kg of LPE  




Plate 4: Effects of different doses of LLP on kidney 
histology of female and male rats in repeated dose 
toxicity study for 28 days as assessed by H & E 
staining (A): female treated group with 250 mg/kg of 
LLP (B): male treated group with 250 mg/kg of LLP 
(C): female treated group with 500 mg/kg of LLP (D): 
male treated group with 500 mg/kg of LLP (E): female 
treated group with 1000 mg/kg of LLP (F): male 
treated group with 1000 mg/kg of LLP. All groups in 
this plate showing normal glomeruli and tubules 




Herbal medicines are gaining popularity in 
developing countries because of their less side 
effects. Such remedies are often believed to be 
harmless, since these treatments are “natural” 
and commonly used for self-medication without 
supervision. Although medicinal plants may 
cause several biological activities in humans, a 
little is known regarding the potential toxicity in 
many of these bioactive substances. 
 
The results of acute toxicity study indicated that 
LPE and LLP didn't cause visible signs of toxicity 
or mortality. Generally, a reduction in body 
weight and internal organ weights is a simple and 
sensitive index of toxicity after exposure to 
potentially toxic substances [17]. In the present 
study, LPE and LLP (2000 mg/kg, per oral) did 
not significantly affect body or organ weight as 
compared to the normal control groups, which 
suggests that the extract did not disturb rat 
growth; this is with the agreement to the toxicity 
classification reported by (Loomis and Hayes 
1996) [18]. 
 
However a 28-days sub-chronic oral toxicity 
testing using repeated doses is widely 
considered satisfactory to assess any possible 
health hazard, and is important even for herbal 
supplements. The present results revealed that 
all parameters in term of organ-to-body weight 
ratios, haematological biochemical values were 
found normal between LPE and LLP treated 
groups compared to normal control group [16]. 
Histological examination of the vital organs 
including the liver and kidney from the treated 
and normal rats showed no apparent histological 
changes, chronic pyelitis (inflammation of renal 
pelvis and calyces), was only focally seen at 
pelvis of the kidney. It is often caused by 
ascending bacterial infection. The renal 
parenchyma was normal in this study. Overall the 
histological examination indicated evidence of 
safety at the tested doses when administered 
orally. The safety of treatment was also 
confirmed by the absence of behavioural 
changes and absence of difference in feed 
consumption between the treated and normal 
control groups. Hence, the results clearly showed 
that oral administration of LPE and LLP are safe 
at the evaluated doses (250, 500 and 1000 




The acute and repeated dose oral toxicity assay 
of LPE and LLP could be very useful in its future 
clinical studies. LPE and LLP seemed to be non-
toxic as was seen after its acute and repeated 
dose oral administrations. The oral lethal dose is 
in excess of 1000 mg/kg. The no-adverse-effect-
level from the present study was determined to 
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